"DAPA VILDA 50/5: Dual Action for Diabetes Control"

DAPA VILDA 50/5 

 Dapagliflozin (5mg), Vildagliptin SR (50mg)

Introduction to DAPA VILDA 50/5

DAPA VILDA 50/5 is a combination medication that includes Dapagliflozin (5mg) and Vildagliptin SR (50mg), designed to effectively manage blood sugar levels in patients with type 2 diabetes. This innovative formulation targets different pathways in the body to improve glucose control and provide comprehensive diabetes management.

Dapagliflozin (5mg)

Mechanism of Action

• Glucose Excretion: Dapagliflozin works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, leading to the excretion of excess glucose through urine.

Usage and Benefits

• Improved Blood Sugar Levels: Regular use of Dapagliflozin can lead to a significant reduction in fasting and postprandial glucose levels.
• Weight Loss Support: Patients may experience weight loss as a beneficial side effect due to the caloric loss through urine.
• Cardiovascular Health: Dapagliflozin has been shown to reduce hospitalization for heart failure in diabetic patients.

Vildagliptin SR (50mg)

Mechanism of Action

• Enhancing Insulin Secretion: Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that helps increase insulin production in the pancreas in response to meals.

Usage and Benefits

• Stable Blood Sugar Control: Vildagliptin helps maintain a more consistent blood sugar level throughout the day.
• Reduces Blood Sugar Spikes: Particularly effective in controlling post-meal glucose surges.
• Pancreatic Health: Supports the pancreas' function and can prevent the exhaustion of insulin-producing cells.

Combining the Powers of DAPA VILDA 50/5

Synergistic Effect for Optimal Control

• The combination of Dapagliflozin and Vildagliptin offers a dual mechanism of action, targeting both insulin production and glucose reabsorption.
• This synergistic effect helps in achieving better glycemic control than either component alone.

Usage and Benefits

• Comprehensive Glucose Management: DAPA VILDA 50/5 effectively reduces high blood sugar levels, catering to the needs of type 2 diabetes patients.
• Convenience and Compliance: The combination in one pill enhances patient compliance, simplifying the medication regimen.

Conclusion

DAPA VILDA 50/5 represents a significant advancement in the treatment of type 2 diabetes, offering a potent combination that targets multiple aspects of diabetes management. With its dual action, it provides effective blood sugar control, promotes cardiovascular health, and supports overall well-being in diabetic patients.  A team of highly skilled professionals in the pharmaceutical field established Steris Healthcare Pvt Ltd in February 2018. Sterispharma is a certified pharmaceutical company by WHO, GMP, and ISO, situated in Navi Mumbai. It is dedicated to delivering high-quality medications at competitive prices to customers across India, adhering to WHO's stringent standards. Through Steris's online pharmacy, customers can conveniently purchase medicines and receive home delivery. Our primary objective at Steris is to offer a comprehensive range of healthcare products to fulfill the diverse requirements of the healthcare industry. Steris is committed to meeting the healthcare sector's demands, whether it's specialized treatments, medications for rare diseases, or essential pharmaceuticals. The range of Steris healthcare products caters to various medical needs, including Cardiology, Asthma, Respiratory, Nasal, Diabetes, Endocrinology, Gastrology, Orthopedics, Anti-infective/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental, and Dermatology.  For further information:  EMAIL:  info@sterispharma.com  / contact@sterispharma.com     CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668   

  BUY NOW